Biol Reprod Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


BOR - Papers in Press, published online ahead of print February 6, 2004.
Biol Reprod 2004, 10.1095/biolreprod.103.026179
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
70/6/1614    most recent
biolreprod.103.026179v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McLennan, I. S.
Right arrow Articles by Koishi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLennan, I. S.
Right arrow Articles by Koishi, K.
Agricola
Right arrow Articles by McLennan, I. S.
Right arrow Articles by Koishi, K.
BIOLOGY OF REPRODUCTION 70, 1614–1618 (2004)
DOI: 10.1095/biolreprod.103.026179
© 2004 by the Society for the Study of Reproduction, Inc.


Immunology

Fetal and Maternal Transforming Growth Factor-ß1 May Combine to Maintain Pregnancy in Mice1

Ian S. McLennan2, and Kyoko Koishi

The Neuromuscular Research Group, The University of Otago, Dunedin, New Zealand


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
One of the mysteries of pregnancy is why a mother does not reject her fetuses. Cytokine-modulation of maternal-fetal interactions is likely to be important. However, mice deficient in transforming growth factor-ß1 (TGFß1) and other cytokines are able to breed, bringing this hypothesis into question. The phenotype of TGFß1 null-mutant mice varies with genetic background. We report here that, in outbred mice, the loss of TGFß1- deficient embryos is influenced by the parity of their mother. This is consistent with the loss of mutants being due to immune rejection. An inbred line of TGFß1+/– mice that supported TGFß1-deficient fetuses had high levels of TGFß1 in their plasma. Analysis of the amniotic fluids in this line indicated that biologically relevant levels of maternal TGFß1 were present in the TGFß1–/– fetuses. These data are consistent with maternal and fetal TGFß1 interacting to maintain pregnancy, within immune-competent mothers.

conceptus, cytokines, growth factors, immunology, pregnancy


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We are immunologically distinct from our mothers. Consequently, successful pregnancies involve mechanisms that prevent the mother's immune system from rejecting her concepti. The placenta has a primary role here as it separates the maternal and fetal blood supplies, thus limiting the exposure of the fetus to the mother. The placenta, however, is not a perfect barrier. Fetal cells enter the maternal blood supply [1] and maternal T cells and antibodies can be detected in viable fetuses [2]. Other mechanisms must therefore be acting in concert with the placenta to suppress fetal rejection.

Immune rejection in the adult is regulated by complex interactions involving multiple cytokines. These interactions are also likely to be important in pregnancy, with successful pregnancy being dependent on an appropriate balance of cytokines at the maternal-fetal interface. T-helper (Th) 2/3-type cytokines, such as the transforming growth factor-betas (TGFßs), interleukin-10 (IL-10), and colony- stimulating factor-1 (CSF-1), appear to promote pregnancy whereas proinflammatory Th1 cytokines, such as tumor necrosis factor-{alpha} and IL-2, are detrimental [35].

The TGFßs are a small family of proteins with three mammalian members, all of which are potent regulators of the immune system. In most circumstances, the TGFßs suppress the activities of immune cells [6]. The three TGFß isoforms are present in the uterus [7, 8] and concepti [9], but have distinct spatial and temporal patterns. TGFß2 is produced by the placenta [7, 10] and has been implicated in creating immune tolerance of the placenta [5]. The distribution of TGFß2 within the fetus is, however, comparatively limited [11], making it unlikely that it is primarily responsible for suppressing immune cells that pass through the placenta. TGFß1 is a better candidate for this role, as it is ubiquitously present in fetal tissues [12, 13]. TGFß1 could also be important for maintenance of the placenta, as decidual cells produce TGFß1, as well as TGFß2 [7, 8].

The phenotype of TGFß1–/– mice is complex and varies with genetic background [14, 15], but to date, there have been no reports of maternal rejection of TGFß1-deficient concepti (fetus plus extraembryonic membranes). However, all of the TGFß1-deficient colonies studied have inbred background that limits the immunological distinction between the mother and her fetuses. We have therefore undertaken a retrospective examination of the breeding records of an inbred and an outbred colony of TGFß1+/– mice, seeking evidence of maternal rejection of fetuses.

As a result of the limited exchange of material between the mother and her conceptus, immune-related conditions such as Rh hemolytic disease are rare during a first pregnancy [16]. This provides a means to assess the physiological role of cytokines in preventing immune-mediated abortion. Simply, if TGFß1 prevents immune rejection of fetuses in vivo, then the loss of TGFß1-deficient fetuses should increase with the parity (number of pregnancies) of their mother. We report here that the loss of TGFß1–/– and TGFß1+/– fetuses in outbred mice follows this pattern.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Animals

All experiments were approved by The University of Otago's Animal Ethics Committee. The majority of the mice were originally bred for experiments that are unrelated to the present study [17, 18].

Swiss Webster mice were obtained from the University of Otago's colony.

The inbred TGFß1+/– colony was a derivative of Prof. T. Doetschman's [14] and was established with mice purchased from The Jackson Laboratory (Bar Harbor, ME). These mice had a mixed 129/Sv x C57BL/6J background. The colony was maintained by mating TGFß1+/– studs and dams. The genotypes of the mice were determined by polymerase chain reaction, as previously described [17].

The nude (Whn–/–) TGFß1–/– colony was maintained by breeding Whn+/–, TGFß1+/– dams with Whn–/–, TGFß1+/– studs and are referred to as outbred/nu. The mothers therefore produced T cells and TGFß1. The founder nude TGFß1+/– mice were generated by breeding TGFß1+/– dams with nude (Whn–/–) studs. The nude mice had an outbred Swiss Webster background (Crl:CD-1nuBR) and were from a local colony, ex Charles River Laboratories (Wilmington, MA). Nude dams were periodically introduced to the colony to maintain its outbred character.

Timed pregnancies were generated by mating TGFß1+/– males and females at 1700 h. The females were examined the following morning at 0700 h for the presence of copulatory plugs. The males were removed to prevent copulation during the daytime. Noon on the day of detection of a plug was defined as E0.5.

An outbred/wt colony was established by crossing inbred TGFß1+/– studs with Swiss Webster dams. The male TGFß1+/– pups resulting from these crosses were then crossed with Swiss Webster dams. The F2 TGFß1+/– dams and studs were mated to analyze the survival of TGFß1+/– fetuses in outbred Swiss Webster mice, lacking the nude mutation.

Collection of Amniotic Fluid

Pregnant dams were anesthetized with pentobarbitone and their abdomens opened. The amniotic fluid of each conceptus was collected by inserting a syringe with a 16-gauge needle through the chorion and amnion. The amniotic fluid was centrifuged at 12 000 x g for 5 min at 4°C to remove cells and immediately snap frozen in liquid nitrogen. The samples were stored at –80°C. The tail of each fetus was collected and used for genotyping [17].

Collection of Platelet-Deficient Plasma

Platelet-deficient plasma was prepared using a standard technique. Mice were anesthetized with diethyl ether and 400 µl of their blood removed by cardiac puncture using a syringe and 16-gauge needle that had been washed with 2% EDTA. The blood was added to a tube containing 40 µl of 2% EDTA at 4°C and then spun at 12 000 x g for 15 min at 4°C.

ELISA

The concentrations of TGFß1 in amniotic fluid and plasma were measured using the Promega Emax Immunoassay system (Promega, Madison, WI) according to the manufacturer's instructions. Each sample was acidified with HCl to a pH of 1.6 for 15 min, neutralized with NaOH, and diluted with the manufacturer's sample buffer to ensure that all measurements were made in the middle of the range of the ELISA (31–1000 pg/ ml). The intraassay variation was 7.7%. The ELISA was specific to TGFß1, with a cross-reactivity of less than 5% with TGFß2 and TGFß3 at 10 ng/ml (Promega).


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Loss of Mutant TGFß1 Concepti Is Related to Parity

Retrospective analysis of the breeding records of two colonies of TGFß1+/– mice was undertaken to assess whether the loss of TGFß1-deficient fetuses was related to parity. The frequency of TGFß1–/– mice surviving to birth in the outbred/nu colony was strongly linked to parity. The loss of TGFß1–/– concepti increased substantially after the first pregnancy, with no mutants surviving in mothers carrying their third or subsequent pregnancy (Fig. 1). The survival of TGFß1–/– concepti was not related to the age of the mother, indicating that the association with parity was not an indirect consequence of mothers being young during their first pregnancy.



View larger version (10K):
[in this window]
[in a new window]
 
FIG. 1. The figure illustrates the frequency of TGFß1–/– pups in litters versus the number of litters that their mothers had conceived (parity). Each bar represents the mean ± the standard error of the mean. The data are expressed as a percentage of that predicted by Mendelian rules. The numbers of litters examined at the various parities were 31 (1), 21 (2), 17 (3), 11 (4), and 20 (5–8). The values for all the experienced mothers (parity >2) were statistically different from the monoparous (parity = 1) value (Student t: #P < 0.05; *P < 0.01). The data were also analyzed using binomial logistic regression. For this analysis, the standard error of the means were adjusted for clustering of dams, as each dam has litters in multiple parity classes. The reduction in the proportion of mutant pups in parity 2 was not significant (P = 0.105). For higher parity, the reduction was highly significant (*P = 0.000). There was no correlation between maternal age and number of mutant pups. The presented data are from the outbred/nu colony

We then examined whether experienced outbred/nu mothers rejected a proportion of their wild-type and heterozygous concepti, along with the mutants. The number of wild-type pups per litter averaged 3.3 and was not correlated with parity (not illustrated). The expected ratio of heterozygous to wild-type concepti is two, which was observed in the litter from monoparous mothers. The ratio with experienced mothers (two or more pregnancies) was 1.5, which is significantly less than expected (P < 0.01, chi-squared). The extent of this loss was maximal with the second litter and relatively constant thereafter (Fig. 2). This suggests that experienced outbred/nu mothers reject approximately one in four of their TGFß1+/– concepti.



View larger version (15K):
[in this window]
[in a new window]
 
FIG. 2. The figure illustrates the frequency of TGFß1+/– pups in litters versus the number of litters that their mothers had conceived (parity). The data are expressed as a ratio of heterozygous to wild-type pups. The numbers of wild type plus heterozygous pups examined at the various parities were 281 (1), 228 (2), 127 (3), 101 (4), 75 (5–8), and 531 (2–8). The combined data for all the experienced mothers (parity 2–8) was significantly different from Mendelian ratios (chi-squared: *P < 0.01). However, due to the smaller n values for the individual parities, only the biparous mothers (parity = 2) were significantly different from the Mendelian ratio (chi-squared: #P < 0.025). The presented data are from the outbred/nu colony

TGFß1–/– concepti were also lost in the inbred colony (Table 1). However, in marked contrast with the outbred/ nu colony, the extent of this loss was unrelated to parity, with mothers able to carry a proportion of their TGFß1–/– embryos to term, even after 11 pregnancies (Table 1). The ratio of heterozygous to wild-type pups was also normal in the inbred colony for all parities (Table 1).


View this table:
[in this window]
[in a new window]
 
TABLE 1. Frequency of genotypes versus parity in the inbred TGFß1+/– colony.*

Inbred TGFß1+/– were then bred to Swiss Webster mice to produce an outbred TGFß1+/– colony that is wild type for the nude mutation (outbred/wt, colony). The number of mutant pups in this colony was also strongly linked to parity (Fig. 3), indicating that the Swiss Webster background is sufficient for the loss of TGFß1-deficient concepti to occur.



View larger version (12K):
[in this window]
[in a new window]
 
FIG. 3. The effect of parity on the genotype of pups derived from heterozygous matings of TGFß1 null mutant mice with a pure Swiss Webster background (outbred/wt colony). Each bar represents the mean ± the standard error of the mean of the number of pups per litter. Ten and seven litters were examined, respectively, from the monoparous and experienced (parity 2–4) mothers. The numbers of wild-type pups are indicated by the gray bars, whereas the white and black bars represent the heterozygous and mutant pups, respectively. The number of mutant pups in the litters from the experienced mothers is significantly different from the number of mutants in the monoparous litters (*, P < 0.01)

Maternal TGFß1 Is Present in Concepti

The amount of maternal TGFß1 in concepti was assessed by comparing the levels of TGFß1 protein in the amniotic fluids of TGFß1+/+, TGFß1+/–, and TGFß1–/– fetuses within a common TGFß1+/– mother (see Table 2). The concentration of TGFß1 in the amniotic fluids of the mutant fetuses was approximately half that of their wild- type littermates (Fig. 4B), indicating that significant maternal transfer of TGFß1 protein had occurred. Heterozygotic concepti had TGFß1 levels that were intermediate between their mutant and wild-type littermates (Fig. 4B). A gene dose relationship was also observed for the concentration of TGFß1 in maternal plasma (Fig. 4A).


View this table:
[in this window]
[in a new window]
 
TABLE 2. Theoretical contribution of maternal and fetal TGFß1 to am niotic TGFß1



View larger version (19K):
[in this window]
[in a new window]
 
FIG. 4. The figure illustrates the concentration of TGFß1 in the plasma of adult inbred mice (A) and amniotic fluids of 16-day-old concepti in inbred mice (B). The bars representing wild-type, heterozygous, and null mutant animals are shaded in black, gray, or white, respectively. The sex of the mice in (A) is indicated beneath the bar using standard symbols or Pr to designate that the females were pregnant. The genotype in (B) represents that of the concepti. All of the mothers in (B) were TGFß1+/– and had been mated with TGFß1+/– studs. Each value is the mean ± the standard error of the mean of either eight (A) or five (B) mice. The values for the heterozygous and mutant mice are significantly different from those of the wild type (Student t; #P < 0.05; *P < 0.01; **P < 0.001). In (A), the values of the heterozygous mice are not significantly different from 50% of the wild-type value. That is, the amount of TGFß1 appears to be correlated with gene dosage

Plasma TGFß1 Is Constant During Pregnancy

The concentration of TGFß1 in the plasma of humans rises during pregnancy [19]. In contrast with this, the level of TGFß1 in the TGFß1+/– dams used in the present study was not different from that of their nonpregnant counterparts (Fig. 4A). The possibility that maternal TGFß1 levels fluctuate during pregnancy was then further examined using Swiss Webster mice. No significant variation in plasma TGFß1 was observed at any stage of pregnancy (Fig. 5).



View larger version (9K):
[in this window]
[in a new window]
 
FIG. 5. The figure illustrates the concentration of TGFß1 in the plasma of Swiss Webster mice during pregnancy. Each value is the mean ± the standard error of the mean of five mice. The concentration in male blood is given on the righthand side of the figure for the purposes of comparison


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Parity-Related Loss of TGFß1-Deficient Concepti

The frequency of TGFß1–/– and TGFß1+/– mice surviving to birth was strongly linked to parity in the outbred/nu colony. This phenomenon was also observed in the outbred/ wt colony, indicating that the presence of the nude (Whn–/–) mutation is not essential for parity-related loss of concepti.

The loss of TGFß1-deficient concepti in the outbred colonies was not associated with maternal age, indicating that the association with parity is not an indirect consequence of more experienced mothers being older. Parity-related reproductive failure is rare and is usually indicative of the involvement of the maternal immune system. With the present study, this is particularly likely, as the fetuses being lost are deficient in a potent suppressor of immune responses.

The loss of TGFß1–/– concepti in the inbred line was unrelated to parity. Several factors may combine here to create this phenomenon. First, the capacity of the inbred mothers to mount an immune attack against their concepti may be very limited. In inbred lines, the mother and her fetuses are genetically similar, which may attenuate (but not abolish) the ability of the mother to recognize her fetuses as foreign. Additionally, the inbred mice analyzed in this study had C57BL/6 ancestry, which can lead to diminished immune responses in some circumstances [20, 21] (see also www.informatics.jax.org/external/festing/search_form.cgi).

Second, the inbred mice had higher plasma levels of TGFß1 than outbred mice (cf., Figs. 4A and 5), which may make the survival of their offspring less dependent on fetal sources of TGFß1 (see below). Last, successful pregnancy is likely to depend on multiple genes, which may be differentially expressed in the inbred and outbred mice. This could lead to different strains of mice having different dependencies on TGFß1 (see below).

Loss of TGFß1-Deficient Concepti in Monoparous Mother

Some TGFß1–/– concepti die early in development due to inadequate development of the yolk sac [14, 22]. The variability of this early death is due to allelic variation in a region of chromosome 5: TGFß1–/– concepti survive when the chromosome is from NIH/Ola or 129 mice but not when it is from C57BL/6 mice [15, 23]. The inbred colony analyzed in this study had a mixed C57BL/6 x 129 background. The loss of TGFß1–/– concepti that occurred in the inbred colony is thus probably due to the selective elimination of the mice with the unfavorable C57BL/6 allele. The loss of TGFß1–/– concepti in the monoparous outbred mothers is suggestive that the unfavorable C57BL/ 6 allele is common in outbred colonies. However, we do not discount the possibility that immune rejection may also contribute to the loss of TGFß1–/– concepti in monoparous outbred litters.

Dual Sources of TGFß1

The TGFß1 in amniotic fluid was observed to be of dual maternal and fetal origins. Amniotic fluid is a mixture of fetal urine and lung secretions [24]. The presence of maternal TGFß1 within the amniotic fluid is thus indicative that maternal TGFß1 passes through the fetus. Consistent with this, TGFß1 protein is bound to the connective tissues of TGFß1 null mutant concepti [18, 25] and intact iodinated TGFß1 is recoverable from fetuses after injection into the mother [25]. Thus, all fetal tissues appear to be bathed in TGFß1 from both the mother and from sources within the fetus (see [26] for the locations of fetal TGFß1 mRNA).

In the inbred line, the amniotic fluid from TGFß1 mutant fetuses had half the level of TGFß1 protein of their wild- type equivalents (see Fig. 4B and Table 2). This implies that the amniotic fluid from the wild-type concepti contained very similar amounts of maternal and fetal TGFß1. This method may, however, underestimate the maternal contribution, as the dams used in this study were TGFß1+/–, which have half the wild-type levels of plasma TGFß1 (Fig. 4A). Thus, in wild-type pregnancies, the amount of maternal TGFß1 in a conceptus may be up to twice that of fetal TGFß1. However, we do not favor too exact a ratio being placed on the relative levels of maternal and fetal TGFß1, as the level of plasma TGFß1 varied with genetic background (cf. Figs. 4 and 5). As a conceptus is genetically different from its mother, it is likely that the ratio of maternal to fetal TGFß1 varies in a natural population. The importance of our observations is that they show that a conceptus has biologically significant amounts of TGFß1 from both its mother and itself.

Are Maternal and Fetal TGFß1 Redundant?

The existence of two sources of TGFß1 raises the issue of whether both are essential for the maintenance of pregnancy. When considering this question, it is important to bear in mind the following. TGFß-dependent phenomena exhibit different dose sensitivities. Mice that are heterozygous null for one of the TGFßs exhibit specific defects, even though they contain 50% of the normal levels of the TGFß [27, 28]. Other defects are only observed when both alleles are mutated [14, 29] (Table 1). Here, 50% of the normal levels of TGFß are sufficient for full function. Further defects emerge when deficiencies in TGFß signaling occur in concert with either deficiencies in other signaling pathways [30, 31] or allelic variations in genes with no obvious relationship to signaling pathways [32]. Consequently, we need to consider the possibilities that 1) maternal and fetal TGFß1 may jointly regulate some aspects of pregnancy/development while independently controlling other aspects and 2) the importance of TGFß1 in controlling immune rejection may be modulated by multiple factors, including the genetic backgrounds of both the mother and her concepti, the immunological similarity between the mother and her concepti, and the immune history of the mother.

With inbred mice, the mothers have high levels of plasma TGFß1 and no parity-related loss of TGFß1-deficient concepti occurs (this study). This indicates that fetal TGFß1 is not essential to prevent parity-related loss of concepti in this colony. This mirrors the situation with inbred neonates where maternal transfer of TGFß1 via milk is sufficient to suppress autoimmune attack in TGFß1–/– pups [14, 33]. Both of these phenomena are, however, in marked contrast with the TGFß1-dependent development of the yolk sac, which appears to be entirely under the control of fetal TGFß1 [32, 34]. This is not surprising, as the defect in the yolk sac is lethal before extensive development of the placenta has occurred. The ability of maternal TGFß1 to reach the concepti would thus be limited.

The situation with the inbred mice also contrasts with that of the multiparous outbred mothers where fetal TGFß1 production is an important determinant of survival: wild- type concepti survive; TGFß1+/– concepti have reduced survival; TGFß1–/– concepti do not survive, even though their amniotic fluids contain approximately 50% of TGFß1 of the wild-type littermates. This suggests that the TGFß1- dependent suppression of parity-related loss of concepti only occurs if the level of TGFß1 exceeds a threshold, as in the deficits observed in TGFß1+/– adults [27].

In summary, the data reported here show that concepti are exposed to significant levels of both fetal and maternal TGFß1. The levels of fetal TGFß1 appear to be a determinant of whether a conceptus is rejected or not, although the evidence clearly indicates that maternal TGFß1 and other factors are also important. In at least some circumstances, these factors may be sufficient to fully compensate for a low level of fetal TGFß1.


    ACKNOWLEDGMENTS
 
Ms. Sarah Booth and Ms. Julie Taylor-Jeffs are thanked for their expert technical assistance and Mr. Peter Herbison for his advice on statistical methods.


    FOOTNOTES
 
1 This study was funded by the Health Research Council of New Zealand and the Marsden Fund. Back

2 Correspondence: Ian S. McLennan, Department of Anatomy and Structural Biology, The University of Otago, P.O. Box 913, Dunedin, New Zealand. FAX: 64 3 479 7254; ian.mclennan{at}stonebow.otago.ac.nz Back

Received: 3 December 2003.

First decision: 6 January 2004.

Accepted: 28 January 2004.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bonney EA, Matzinger P. The maternal immune system's interaction with circulating fetal cells. J Immunol 1997 158:40-47[Abstract]
  2. Piotrowski P, Croy BA. Maternal cells are widely distributed in murine fetuses in utero. Biol Reprod 1996 54:1103-1110[Abstract]
  3. Entrican G. Immune regulation during pregnancy and host-pathogen interactions in infectious abortion. J Comp Pathol 2002 126:79-94[CrossRef][Medline]
  4. Raghupathy R. Pregnancy: success and failure within the Th1/Th2/ Th3 paradigm. Semin Immunol 2001 13:219-227[CrossRef][Medline]
  5. Clark DA, Arck PC, Chaouat G. Why did your mother reject you? Immunogenetic determinants of the response to environmental selective pressure expressed at the uterine level. Am J Reprod Immunol 1999 41:5-22
  6. Letterio JJ, Roberts AB. Regulation of immune responses by TGF- beta. Annu Rev Immunol 1998 16:137-161[CrossRef][Medline]
  7. Das S, Flanders K, Andrews G, Dey S. Expression of transforming growth factor-beta isoforms (beta 2 and beta 3) in the mouse uterus: analysis of the periimplantation period and effects of ovarian steroids. Endocrinology 1992 130:3459-3466[Abstract]
  8. Chen H, Yelavarthi K, Hunt J. Identification of transforming growth factor-beta 1 mRNA in virgin and pregnant rat uteri by in situ hybridization. J Reprod Immunol 1993 25:221-233[CrossRef][Medline]
  9. Pelton RW, Saxena B, Jones M, Moses HL, Gold LI. Immunohistochemical localization of TGFbeta1, TGFbeta2, and TGFbeta3 in the mouse embryo—expression patterns suggest multiple roles during embryonic development. J Cell Biol 1991 115:1091-1105[Abstract/Free Full Text]
  10. Clark DA, Flanders KC, Hirte H, Dasch JR, Coker R, Mcanulty RJ, Laurent GJ. Characterization of murine pregnancy decidua transforming growth factor beta 1. transforming growth factor beta 2-like molecules of unusual molecular size released in bioactive form. Biol Reprod 1995 52:1380-1388[Abstract]
  11. Pelton RW, Nomura S, Moses HL, Hogan BLM. Expression of transforming growth factor beta2 RNA during murine embryogenesis. Development 1989 106:759-767[Abstract/Free Full Text]
  12. Heine UL, Munoz EF, Flanders KC, Ellingsworth LR, Lam H-YP, Thompson NL, Roberts AB, Sporn MB. Role of transforming growth factor-beta in the development of the mouse embryo. J Cell Biol 1987 105:2861-2876[Abstract/Free Full Text]
  13. McLennan IS. Localization of transforming growth factor beta1 in developing muscles: implications for connective tissue and fibre type pattern formation. Dev Dyn 1993 197:281-290[Medline]
  14. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin MY, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T. Targeted disruption of the mouse transforming growth factor-beta1 gene results in multifocal inflammatory disease. Nature 1992 359:693-699[CrossRef][Medline]
  15. Bonyadi M, Rusholme SA, Cousins FM, Su HC, Biron CA, Farrall M, Akhurst RJ. Mapping of a major genetic modifier of embryonic lethality in TGF beta 1 knockout mice. Nat Genet 1997 15:207-211[CrossRef][Medline]
  16. Avery ME, Taeusch HW. Schaffer's Diseases of the Newborn. Philadelphia: WB Saunders; 1984
  17. Poussart Y, Koishi K, McLennan IS. Connective tissue formation in the skeletal muscles of transforming growth factor-beta 1 (TGF-beta1) null mutant mice. Basic Appl Myol 1998 8:121-128
  18. McLennan IS, Poussart Y, Koishi K. Development of skeletal muscles in transforming growth factor-beta 1 (TGF-beta1) null-mutant mice. Dev Dyn 2000 217:250-256[CrossRef][Medline]
  19. Ogasawara MS, Aoki K, Aoyama T, Katano K, Iinuma Y, Ozaki Y, Suzumori K. Elevation of transforming growth factor-beta1 is associated with recurrent miscarriage. J Clin Immunol 2000 20:453-457[CrossRef][Medline]
  20. James K, Milne I. The effect of anti-lymphocytic antibody on the humoral immune response in different strains of mice. I. The response to bovine serum albumin. Immunology 1972 23:897-909[Medline]
  21. Pinchuck P, Maurer PH. Antigenicity of polypeptides (poly alpha amino acids). XVI. Genetic control of immunogenicity of synthetic polypeptides in mice. J Exp Med 1965 122:673-679[Abstract]
  22. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta1 knock out mice. Development 1995 121:1845-1854[Abstract]
  23. Kallapur S, Ormsby I, Doetschman T. Strain dependency of TGF- beta1 function during embryogenesis. Mol Reprod Dev 1999 52:341-349[CrossRef][Medline]
  24. Brace RA. Physiology of amniotic fluid volume regulation. Clin Obstet Gyn 1997 40:280-289
  25. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB. Maternal rescue of transforming growth factor-beta 1 null mice. Science 1994 264:1936-1938[Abstract/Free Full Text]
  26. Lehnert SA, Akhurst RJ. Embryonic expression pattern of TGF beta type 1 RNA suggests both paracrine and autocrine mechanisms of action. Development 1988 104:263-273[Abstract]
  27. Boivin GP, Molina JR, Ormsby I, Stemmermann G, Doetschman T. Gastric lesions in transforming growth factor beta-1 heterozygous mice. Lab Invest 1996 74:513-518[Medline]
  28. Dunker N, Schmitt K, Schuster N, Krieglstein K. The role of transforming growth factor beta-2, beta-3 in mediating apoptosis in the murine intestinal mucosa. Gastroenterology 2002 122:1364-1375[CrossRef][Medline]
  29. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T. TGF beta2 knockout mice have multiple developmental defects that are nonoverlapping with other TGF beta knockout phenotypes. Development 1997 124:2659-2670[Abstract]
  30. Dunker N, Krieglstein K. TGFbeta2 (–/–) TGFbeta3 (–/–) double knockout mice display severe midline fusion defects and early embryonic lethality. Anat Embryol 2002 206:73-83[CrossRef][Medline]
  31. Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul- Chantler S, Grail D, Small C, Weinberg RA, Sizeland AM, Zhu HJ. Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol Cell Biol 2003 23:4371-4385[Abstract/Free Full Text]
  32. Tang Y, McKinnon ML, Leong LM, Rusholme AB, Wang S, Akhurst RJ. Genetic modifiers interact with maternal determinants in vascular development of TGFbeta1–/– mice. Hum Mol Genet 2003 12:1579-1589[Abstract/Free Full Text]
  33. Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB. Transforming growth factor beta1 controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta1 null mouse phenotype. Proc Natl Acad Sci U S A 1993 90:9944-9948[Abstract/Free Full Text]
  34. Chagraoui H, Giraudier S, Vainchenker W, Wendling F. Adenoviral supply of active transforming growth factor-beta1 (TGF-beta1) did not prevent lethality in transforming growth factor-beta1-knockout embryos. Eur Cytokine Netw 2001 12:561-567[Medline]



This article has been cited by other articles:


Home page
EndocrinologyHome page
W. V. Ingman, R. L. Robker, K. Woittiez, and S. A. Robertson
Null Mutation in Transforming Growth Factor {beta}1 Disrupts Ovarian Function and Causes Oocyte Incompetence and Early Embryo Arrest
Endocrinology, February 1, 2006; 147(2): 835 - 845.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
70/6/1614    most recent
biolreprod.103.026179v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McLennan, I. S.
Right arrow Articles by Koishi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLennan, I. S.
Right arrow Articles by Koishi, K.
Agricola
Right arrow Articles by McLennan, I. S.
Right arrow Articles by Koishi, K.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS